
Assertio Holdings ASRT
$ 11.92
1.24%
Quarterly report 2025-Q3
added 11-10-2025
Assertio Holdings DPO Ratio 2011-2026 | ASRT
Annual DPO Ratio Assertio Holdings
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 131 | 123 | 248 | 272 | 622 | 121 | 74.1 | 62 | 179 | 30.8 | 470 | 143 | 159 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 622 | 30.8 | 203 |
Quarterly DPO Ratio Assertio Holdings
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 85.3 | 84.4 | 138 | - | 172 | 159 | 119 | - | 195 | 166 | 102 | - | 202 | 181 | 165 | - | 361 | 315 | 292 | - | 209 | 258 | 1.01 K | - | 659 | 348 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.01 K | 84.4 | 261 |
DPO Ratio of other stocks in the Drug manufacturers industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Aerie Pharmaceuticals
AERI
|
116 | - | - | $ 754 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
58.9 | - | 7.5 % | $ 6.35 M | ||
|
Catalent
CTLT
|
41.8 | - | - | $ 11.5 B | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
345 | - | 0.86 % | $ 117 M | ||
|
Canopy Growth Corporation
CGC
|
52.8 | $ 1.07 | -0.47 % | $ 115 M | ||
|
DURECT Corporation
DRRX
|
519 | - | - | $ 50.1 M | ||
|
Endo International plc
ENDP
|
39.3 | - | - | $ 28.9 M | ||
|
Agile Therapeutics
AGRX
|
352 | - | 10.11 % | $ 58.2 M | ||
|
Evoke Pharma
EVOK
|
5.36 K | - | - | $ 36.6 M | ||
|
Alimera Sciences
ALIM
|
309 | - | - | $ 142 M | ||
|
Harrow Health
HROW
|
199 | $ 38.95 | -27.32 % | $ 1.43 B | ||
|
Cronos Group
CRON
|
212 | $ 2.62 | -0.57 % | $ 1.36 B | ||
|
Avadel Pharmaceuticals plc
AVDL
|
224 | - | - | $ 2.06 B | ||
|
Jupiter Wellness
JUPW
|
215 | - | - | $ 33.6 M | ||
|
China Pharma Holdings
CPHI
|
33.4 | $ 0.55 | -0.97 % | $ 9.61 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
775 | $ 4.5 | -7.02 % | $ 63.3 M | ||
|
Aurora Cannabis
ACB
|
-807 | $ 3.52 | -5.26 % | $ 86.3 M | ||
|
Athenex
ATNX
|
111 | - | -23.39 % | $ 1.76 M | ||
|
Organogenesis Holdings
ORGO
|
94 | $ 2.86 | -4.67 % | $ 377 M | ||
|
Emergent BioSolutions
EBS
|
55.8 | $ 8.87 | -1.33 % | $ 454 M | ||
|
ProPhase Labs
PRPH
|
45.4 | - | - | $ 5.07 M | ||
|
Radius Health
RDUS
|
274 | - | - | $ 1.42 B | ||
|
Rockwell Medical
RMTI
|
20.9 | $ 0.9 | 0.37 % | $ 21 M | ||
|
Evolus
EOLS
|
59.4 | $ 4.21 | -1.86 % | $ 261 M | ||
|
Bausch Health Companies
BHC
|
78.1 | $ 5.77 | -3.11 % | $ 2.11 B | ||
|
Lannett Company
LCI
|
36.8 | - | 1.15 % | $ 7.11 M | ||
|
Eagle Pharmaceuticals
EGRX
|
75.6 | - | -39.89 % | $ 27.7 M | ||
|
Perrigo Company plc
PRGO
|
64.2 | $ 11.38 | -7.97 % | $ 1.58 B | ||
|
Pacira BioSciences
PCRX
|
37.3 | $ 22.06 | 3.67 % | $ 1.02 B | ||
|
PetIQ
PETQ
|
54.2 | - | 1.64 % | $ 400 M | ||
|
OptiNose
OPTN
|
194 | - | - | $ 1.08 B | ||
|
Recro Pharma
REPH
|
6.63 | - | -4.76 % | $ 65.3 M | ||
|
SCYNEXIS
SCYX
|
20.2 | $ 0.73 | -2.19 % | $ 34.9 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
32.3 | $ 2.76 | -2.66 % | $ 3.43 M | ||
|
TherapeuticsMD
TXMD
|
723 | $ 2.26 | 1.0 % | $ 23.6 M | ||
|
Tilray
TLRY
|
53 | $ 7.37 | -2.97 % | $ 4.55 B | ||
|
Veru
VERU
|
264 | $ 2.54 | -3.05 % | $ 343 M | ||
|
Viatris
VTRS
|
64 | $ 15.09 | -3.89 % | $ 18.1 B | ||
|
cbdMD
YCBD
|
84 | $ 0.79 | -2.48 % | $ 3.41 M |